ACTEP2014: Symp Experience in STEMI & NSTEMI & UA ACS cases in ED Ramathibodi Hospital
1. Ticagrelor: Experience in STEMI & NSTEMI & UA ACS cases in ED Ramathibodi hospital
Yuwares Sittichanbuncha.Assist.Prof.
Emergency Department
Ramathibodi Hospital Medical School
Mahidol University
5. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2011;32(23):2999-3054.
17. Chest pain prevalence in Rama ED
2011
2012
2013(6mos)
CC: Chest pain
858
906
376
Acute MI
115 (12%)
111 (12.25%)
59 (15.7%)
18.
19.
20.
21.
22. •Conclusion from PLATO trial
•Primary endpoint: Death from vascular causes(MI,CVA) ,Mortality ,MI ,Stent thrombosis decrease in Tecagrelor group
•CVA, Major Bleeding no dfference between Tecagrelor and Clopidogrel
27. Inhibition of platelet reactivity
Gurbel PA, et al. Circulation. 2009;120:2577-2585.
[Gurbel 2009:B]
IPA, inhibition of platelet activity
28. Inhibition of platelet reactivity
Gurbel PA, et al. Circulation. 2009;120:2577-2585.
[Gurbel 2009:B]
IPA, inhibition of platelet activity
29. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation.2010;122:2131– 41.
30.
31.
32.
33.
34. คาถาม สาหรับ กูรู
•ข้อแนะนาสาหรับแพทย์ หากพบกรณีเช่นนี้ที่ รพช. ก่อน refer ?
•Antiplatelet of choice?
•Take home message?